MUMBAI, India, May 1 -- Intellectual Property India has published a patent application (202611022870 A) filed by Swami Vivekanand Subharti University, Meerut, Uttar Pradesh, on Feb. 26, for 'adaptive biomarker-driven, ratio-critical epigenetic modulation platform comprising histone deacetylase inhibitors and plant-derived polyphenols with synchronized controlled release architecture.'
Inventor(s) include Priyadarshini Soni; and Akansha Singh.
The application for the patent was published on May 1, under issue no. 18/2026.
According to the abstract released by the Intellectual Property India: "The present invention relates to an adaptive, biomarker-driven, ratio-critical epigenetic modulation platform comprising at least one histone deacetylase (HDAC) inhibitor and at least one plant-derived polyphenolic compound formulated within a predefined molar ratio of 1:3.5 to 1:6.5. The composition is engineered to produce synergistic amplification of histone acetylation while reducing dose-dependent systemic toxicity associated with HDAC inhibitor monotherapy. In specific embodiments, the HDAC inhibitor is selected from vorinostat, panobinostat, belinostat, romidepsin, or valproic acid, and the polyphenol is selected from quercetin, curcumin, resveratrol, or epigallocatechin gallate. The formulation may be incorporated into a synchronized controlled-release delivery system, including nanoparticle-based or dual-layer sustained-release architectures, enabling sequential pharmacokinetic release. The invention further includes a biomarker-guided therapeutic method wherein patient-specific epigenetic and inflammatory markers are assessed to optimize dosage ratio and administration regimen, thereby enhancing therapeutic efficacy, minimizing adverse effects, and improving treatment outcomes in epigenetically mediated disorders."
Disclaimer: Curated by HT Syndication.
